Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: A study in healthy volunteers

  title={Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: A study in healthy volunteers},
  author={Didier Coquoz and Herv{\'e} Claude Porchet and Pierre Dayer},
  journal={Clinical Pharmacology \& Therapeutics},
The antinociceptive effect of three antidepressants with different postulated modes of action, 75 mg desipramine, 225 mg fluvoxamine, and 450 mg moclobemide, was evaluated after single oral dosing in a randomized, double‐blind, placebo‐controlled crossover study in 10 healthy volunteers. Experimental pain thresholds (polysynaptic R‐III reflex and subjective pain rating) were monitored over 23 hours. Compared with placebo, all drugs induced significant subjective pain threshold increases… 

Contribution of monoaminergic modulation to the analgesic effect of tramadol.

1. In humans, the central analgesic effect of tramadol 100 mg orally is only partially reversed by the opioid antagonist naloxone (0.8 mg intravenously). As suggested by in vitro and animal data

Analgesic Effect of Antidepressant Drugs

Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats

It is likely that central α1 adrenoceptors and 5-HT2 receptors are predominantly involved in imipramine- and desipramines-induced antinociception, and classical TCAs are likely to have a therapeutic advantage over SSRIs for pain control.

A comparative study of antinociceptive effect of paroxetine with pethidine in acute pain in albino rats

Efficacy of Paroxetine is almost equal to that of standard drug pethidine in acute pain management and may be mediated via central and peripheral mechanisms.

Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain.

Paroxetine-induced antinociception, similar to morphine, suggests an involvement of direct or indirect action (via an increase in release of endogenous opioid peptide(s) at opioid receptor sites and an involved of serotonergic mechanisms mainly at the receptor level.

Effect of single-dose imipramine on chronic low-back and experimental pain. A randomized controlled trial

The present study failed to demonstrate an immediate analgesic effect of imipramine on low-back pain, suggesting that anti-nociceptive effects as assessed by quantitative sensory tests may depend on CYP2D6 genotype, indicating that metabolizer status should be accounted for when future studies with tricyclic antidepressants are undertaken.

Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.

A twice daily regimen of CHF3381 appears to be adequate from a pharmacokinetic and pharmacodynamic perspective and there were no significant effects of CHf3381 on attention, motor co-ordination or memory at any of the doses.

The Pharmacology of Tramadol

Experimental and clinical data suggest that tramadol may also exert its analgesic effect through direct modulation of central monoaminergic pathways, and this metabolite shows a higher affinity for opioid receptors than the parent drug.

Effect of gender on antinociceptive effect of paroxetine in hot plate test in mice




Central analgesic effect of acetaminophen but not of aspirin

Findings show that acetaminophen‐induced analgesia is centrally mediated, in contrast to aspirin, and the time delay between plasma concentration kinetics and acetaminphen analgesic effect is another argument in favor of its direct action on the central nervous system.

Analgesic activity of tricyclic antidepressants

The actions of amitriptyline were not affected by the specific opiate antagonist naloxone but were markedly attenuated in animals whose monoamine levels had been depleted with reserpine, and central mechanisms appear important since amitripyline was potent when administered intracerebroventricularly.

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

It is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man.

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

In patients with depressive illness, fluvoxamine offers a suitable alternative to tricyclic antidepressants and may be especially valuable in patients with concomitant cardiovascular disease, and those unresponsive to or unable to tolerate tricyClic antidepressants.

Desipramine relieves postherpetic neuralgia

It is concluded that desipramine administration relieves postherpetic neuralgia and that pain relief is not mediated by mood elevation, and blockade of norepinephrine reuptake, an action shared by desIPramine, amitriptyline, and other antidepressant agents that have relieved neuropathic pain, may be involved in relief of postherPetic Neuralgia.

Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.

Compared with earlier results obtained with imipramine dosed on the basis of plasma level monitoring, clomipramines on fixed doses appeared less efficacious whereas the side effect profiles were the same.